NewCardio, Inc. (NWCI.OB) – Revolutionizing the Electrocardiograph
NewCardio, Inc., through its patent-pending, innovative technology, is poised to transform the landscape of electrocardiography (ECG). The company has developed, and is currently working to commercialize, a three-dimensional ECG platform that stands to seriously improve upon traditional methods. In addition to a dramatic increase in diagnostic accuracy, the NewCardio 3D ECG works faster, and with greater cost-effectiveness than the standard 12 lead ECG. NewCardio's advanced systems aid not only in the diagnosis of heart disorders, but also in clinical pharmaceutical trials with respect to the evaluation of a drug's potential cardiac toxicity. This should allow the company to become a…